日韩视频婷一区,老鸭窝AV导航,无码一区二区精品

Global Biopharma Layoffs May 2026 Layoffs Biopharma layoffs in 2026 continue to reshape the industry as companies including Takeda, Novartis, Replimune, Passage Bio and Autolus Therapeutics cut jobs, restructure operations and reduce costs amid pipeline setbacks, strategic reorganizations and market pressures.
Global Biopharma Layoffs March 2026 Layoffs Global Biopharma companies including Merck, Baye, and Novartis announce workforce reductions in March 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Global Biopharma Layoffs January 2026 Layoffs This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs October 2025 Layoffs This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Takeda's 2024 Financial report Market Trend Takeda projects $11B in peak sales from three key drug candidates—TAK-279, TAK-861, and TAK-121—while restructuring its pipeline to drive future growth and profitability.
Takeda Shuts Down EGFR, B7-H3 Programs Takeda Takeda announces major R&D cuts, discontinuing EGFR and B7-H3 oncology projects from its $525M Maverick deal, and streamlining other pipelines to focus on high-potential therapies.
Takeda's 2024 Q4 Financial report Market Trend Takeda's 2024 fiscal report shows 7.4% revenue growth to ￥4.58T, driven by strong core business and R&D breakthroughs. Key segments include GI, rare diseases, oncology. Outlook for 2025 remains stable despite VYVANSE competition.
Top 10 Global Pharmaceutical Giants in Autoimmune Business in 2024 Autoimmune The autoimmune sector saw explosive growth in 2024, with mergers and acquisitions skyrocketing by 150%. Giants like AbbVie, J&J, and Eli Lilly are reshaping the landscape. Explore the Top 10 revenue rankings in the autoimmune business and future trends.
Takeda 2024 Q3 Financial Report Financial statements Takeda’s 2024 financial report shows a $290M revenue for Fuquatinib and strong growth across its key segments. The company also announces CEO succession with Julie Kim to succeed Christophe Weber in 2026.
Top 10 Immunology Drugs to Watch in 2024 AbbVie Explore the top 10 best-selling immunology drugs of 2023, including Humira, Dupixent, Stelara, and more. Discover how these innovative therapies are shaping the market, driving clinical breakthroughs, and overcoming competitive challenges.

<Pre12 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水